Our study demonstrates increased use of RS in guiding adjuvant treatment decisions in node-positive disease.doi:10.1007/s10549-020-05931-9Katya LoskRachel A FreedmanAlison LawsOlga KantorTari A KingBreast Cancer Research and Treatment
CT-based Planning for Node Positive Breast Cancer Does Not Result in Excess Lung and Heart DosesNeoplasms of the oral cavitypostoperative radiation therapyconcurrent chemotherapySuicide gene therapy has become an effective therapy for breast cancer, and ultrasound targeted microbubble destruction (UTMD) ...
Mislabeled Figures:In the Original Contribution entitled “Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer” published in the April 12, 2006, issue ofJAMA(2006;295:1658-1667), incorrect titles and legends were matched with the figures. The ...
Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: an up-to-date meta-analysis of 3,578 patients. Breast. 2021;59:256-269. doi:10.1016/j.breast.2021.07.015PubMedGoog...
Gene expression and benefit of chemotherapy in women with node-negative, oestrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726–3734 (2006). Article CAS Google Scholar Bartlett, J. M. et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK...
The CheckMate-7FL and KEYNOTE-756 trials provide robust evidence for the efficacy of neoadjuvant chemo-immunotherapy in high-risk, early-stage hormone receptor-positive (HER2-negative) breast cancer, and an opportunity to personalize therapy in this population. ...
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, ran... node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide...
4.Gilcrease MZ,Woodward WA,Nicolas MM,et al.Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.AJ Surg Pathol 2009;33:759-67. 5.Denkert C,Seither F,Schneeweiss A,et al...
Breast cancer is a heterogeneous disease, and within the HER-2 positive subtype this is highly exemplified by the presence of substantial phenotypical and clinical heterogeneity, mostly related to hormonal receptor (HR) expression. It is well known how HER-2 positivity is commonly associated with ...
4.Gilcrease MZ,Woodward WA,Nicolas MM,et al.Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.AJ Surg Pathol 2009;33:759-67. 5.Denkert C,Seither F,Schneeweiss A,et al.Articles Clinical and molecular characteristics of HER2-low-positive breast...